Last reviewed · How we verify
Thromboembolism due to Prosthetic Heart Valves — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Coumadin | warfarin | Generic (originally Wisconsin Alumni Research Foundation) | Vitamin K antagonist (anticoagulant) | Vitamin K epoxide reductase complex subunit 1-like protein 1, Cytochrome P450 2C9, Proprotein convertase subtilisin/kexin type 7 | 1954-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Generic (originally Wisconsin Alumni Research Foundation) · 1 drug in Thromboembolism due to Prosthetic Heart Valves
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Thromboembolism due to Prosthetic Heart Valves:
- Thromboembolism due to Prosthetic Heart Valves treatment updates — RSS
- Thromboembolism due to Prosthetic Heart Valves treatment updates — Atom
- Thromboembolism due to Prosthetic Heart Valves treatment updates — JSON
Cite this brief
Drug Landscape (2026). Thromboembolism due to Prosthetic Heart Valves — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/thromboembolism-due-to-prosthetic-heart-valves. Accessed 2026-06-10.
Related
- Thromboembolism due to Prosthetic Heart Valves full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing